newsfilter
← Latest News
PR Newswire·

Aeglea BioTherapeutics Provides Clinical Progress and Regulatory Update for Homocystinuria Program

AUSTIN, Texas, Oct. 4, 2022 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare metabolic diseases, today announced